C&CAUSES & WHAT WE KNOW
Causes & What We Know/November 4, 2026/2 min read

Early Screening Can Identify Type 1 Diabetes Before It Develops

A new study from Poland shows that testing first-degree relatives of people with Type 1 diabetes for specific autoantibodies can catch the disease in its preclinical stage—before symptoms appear.

Research summaryPubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

  • About 5.4% of first-degree relatives screened showed signs of preclinical Type 1 diabetes based on the presence of two or more autoantibodies
  • Early detection allowed doctors to identify people progressing to Type 1 diabetes before dangerous complications like diabetic ketoacidosis (DKA) could develop
  • Among those with autoantibodies, GAD antibodies were the most common, while insulin antibodies were least common
  • Early screening and monitoring in at-risk family members creates an opportunity for timely intervention

What the Study Looked At

Researchers in Poland conducted a screening program to identify children and adolescents at risk of developing Type 1 diabetes. They focused on first-degree relatives—siblings, children, and parents—of people already diagnosed with Type 1 diabetes, since these family members have a significantly higher risk than the general population.

The study involved 1,275 first-degree relatives from 14 clinical centers across Poland. All participants had their blood tested for islet autoantibodies, the immune markers that signal the body is beginning to attack the insulin-producing cells in the pancreas.

What They Found

Overall, 8.1% of participants tested positive for at least one autoantibody. However, researchers focused on those with two or more autoantibodies present, since multiple antibodies are a stronger indicator of preclinical Type 1 diabetes. This more stringent criterion identified 69 subjects, or 5.4% of all participants.

Among those with autoantibodies, glutamic acid decarboxylase (GAD) antibodies were the most frequently detected. Insulin antibodies were the least common. When participants underwent metabolic testing with an oral glucose tolerance test and blood sugar measurements, 10 people showed clear evidence of Type 1 diabetes development.

Early Detection Prevented Serious Complications

What stands out from this research is that none of the 10 people diagnosed during the screening program developed diabetic ketoacidosis (DKA), a life-threatening emergency that can occur when Type 1 diabetes goes undiagnosed. This suggests that early identification through screening allows doctors to intervene before the disease progresses to a dangerous stage.

By catching preclinical Type 1 diabetes through autoantibody screening, follow-up and intervention became possible at a point when blood sugar levels were still normal—before the symptoms and complications of active diabetes took hold.

Why This Matters for Families

This study reinforces the value of screening first-degree relatives of people with Type 1 diabetes. Because family members already carry increased genetic risk, testing them for the specific autoantibodies that signal the disease process provides a window of opportunity for monitoring and potentially delaying or preventing clinical onset.

Early detection means families and their doctors have time to prepare, establish relationships with diabetes care teams, and explore options for intervention—rather than facing an emergency diagnosis with diabetic ketoacidosis or other acute complications.

Evidence label

Source: Pediatric diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

From Type1Cure

Read more of our own writing in Stories

More evidence-labeled coverage across the Type1Cure library.